San Diego-dependent Viking Therapeutics marked alone as a significant competitor from the weight loss drug industry in February after revealing promising facts from the mid-stage demo of experimental drug VK2735, which advised it rivaled—and outperformed—Novo and Lilly drugs when presented as being a weekly injection As well as in March the com